2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 248

Is the Basdai Score Driven By Pain in Ankylosing Spondylitis Patients Treated with Anti-TNF?
Abstract Number: 2556

Is the Degree of NSAID Treatment in Early Axial Spondyloarthritis a Reflection of the physician’s Diagnosic Confidence? Results from the DESIR Cohort
Abstract Number: 711

Is the Disease-Specific Lupusqol Sensitive to Changes of Disease Activity in SLE Patients after Treatment of a Flare?
Abstract Number: 224

Is the Protective Effect of Obesity Against Hip Fracture Due to Changes of Proximal Femur Shape?
Abstract Number: 163

Is the Rate of Skin Reactions to Febuxostat Increased in Patients with a History of Skin Intolerance to Allopurinol? a Retrospective, Hospital-Based Study Involving 101 Patients Consecutively Treated with Allopurinol and Febuxostat
Abstract Number: 2480

Is there a Difference in the Effectiveness in the Treatment of Rheumatoid Arthritis with Rituximab when Using a Dose of 1 or 2 Grams per Cycle? a Systematic Review
Abstract Number: 1600

Is There a Role for Inflammasome Activation in PsA Pathogenesis and Its Comorbidities?
Abstract Number: 3

Is There an Association Between Persistently High Positive Antiphospholipid Antibody Profile and Organ Damage Accrual in Lupus Patients?
Abstract Number: 2507

Is There an Autoinflammatory Component in Rheumatoid Arthritis Associated with Better Response to Anakinra (Kineret^®)?
Abstract Number: 599

Is There Any Gender Specific Difference in the Cut Off Values of Ankylosing Spondylitis Disease Activity Score (ASDAS) in Patients with Axial Spondyloarthritis?
Abstract Number: 631

Joint and Bone Related Pathways Discriminate Psoriatic Arthritis Lesional Skin from Psoriasis vulgaris Lesional Skin
Abstract Number: 2711

Joint and Tendon Involvement Predict Severe Disease Progression in Systemic Sclerosis: A Prospective Study
Abstract Number: 1568

Joint Damage Is Not Associated with Smoking Status in Patients with Psoriatic Arthritis
Abstract Number: 431

Joint Dermal Temperature Specifically Identifies the Individual RA Patient Most Likely to Develop Radiographic Change on Sharp Score; An Exam in Less Than a Minute Can Predict Who Specifically Needs Biologic Therapy
Abstract Number: 2035

Joint Distribution and Outcome in 350 Patients with Monoarthritis of Less Than 16 Weeks Duration: Data from a Multicenter Longitudinal Observational Study in Eastern Norway

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].